AUS
NZ
UK
CA
USA
IND
Dimerix Limited (ASX:DXB) has announced the commencement of patient recruitment for its ‘ACTION3’ Phase 3 clinical trial. This significant milestone involves enrolling adolescent patients aged 12 to 17 with kidney disease in Mexico. The selection of this location marks a crucial step in advancing the clinical study.
Expansion of Clinical Trial Sites
In addition to the Mexican sites, Dimerix is expanding its research efforts to include 14 specialist pediatric clinical sites across Argentina, the United Kingdom, and the United States. This broadening of scope underscores the company's commitment to addressing pediatric kidney disease on a global scale. Furthermore, the appointment of Dr. Howard Trachtman, an esteemed nephrologist from NYU School of Medicine, to the Dimerix board highlights the company’s dedication to enhancing its expertise in nephrology.
Dr. Trachtman expressed enthusiasm about continuing his collaboration with Dimerix, emphasizing the significant unmet need in treating Focal Segmental Glomerulosclerosis (FSGS). Despite its prevalence and serious outcomes in both children and adults, FSGS currently lacks approved therapies to delay or prevent progression to kidney failure.
ACTION3 Trial Details and Funding
The ACTION3 Phase 3 clinical trial will involve blinded, randomized participants who will receive either a placebo or DMX-200, with a follow-up period extending over two years. Dimerix has indicated that it possesses sufficient funds to support the study through its anticipated interim analysis, projected to occur around mid-2025.
The trial aims to provide valuable insights into the efficacy and safety of DMX-200 for treating FSGS in adolescents. As Dimerix continues to progress with its clinical research, the company’s efforts are poised to contribute significantly to the field of nephrology and pediatric kidney disease treatment.
